Main > EMERGENCY MEDICINE (*) > USA. I. GVHD>Treat.>JAK1/JAK2 Inh.>

---

USA. I. GVHD>Treat.>JAK1/JAK2 Inh.>'s subsections
(*) EU CE Mark Date: 2022. 05.05
(*) USA Acute OK: 2019. 05.24
(*) USA Chronic OK: 2021. 09.22
>Tablets
Company
Company Licensee EU
Generic Name: Ruxolitinib
GVHD: Graft Versus Host Dis.
JAK: JAnus Kinase
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 11
Patent>UpDate: 2022. 07.19
RTM Outside USA
RTM Outside USA Web-Site
RTM USA
RTM USA Web-Site

USA. I. GVHD>Treat.>JAK1/JAK2 Inh.>'s products
This section has no products